Clinical Trials Browser

Phase 1/2 × Carcinoma, Non-Small-Cell Lung × nintedanib × Clear all

NCT03377023 2026-01-22

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Phase 1/2 Active not recruiting

66 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung